Jade Biosciences closes $172.5m public offering
Jade Biosciences, Inc. has successfully closed its public offering of 11,500,000 shares of common stock at $15.00 per share, generating $172.5 million in gross proceeds. The offering included the full exercise of the underwriters' option to purchase an additional 1,500,000 shares. Net proceeds will be used to fund clinical trials, preclinical studies, manufacturing, research and development, and general corporate purposes. The securities were offered under a shelf registration statement on Form S-3 declared effective by the SEC on May 15, 2026. Jefferies, TD Cowen, and UBS Investment Bank acted as joint book-running managers, with LifeSci Capital as passive book-running manager and BTIG as lead manager.
*this image is generated using AI for illustrative purposes only.
Jade Biosciences, Inc. has closed its public offering of 11,500,000 shares of common stock, including the full exercise of the underwriters' option to purchase additional shares, at a price of $15.00 per share. The offering generated gross proceeds of $172.5 million before deducting underwriting discounts, commissions, and other offering expenses. All shares were sold by Jade Biosciences to fund its ongoing operations and development programs.
The company plans to allocate the net proceeds from this offering, along with its existing cash, cash equivalents, and investments, toward clinical trials, preclinical studies, and manufacturing. Additionally, funds will support research and development activities, capital expenditures, working capital, and other general corporate purposes. This capital injection is expected to advance Jade Biosciences' pipeline of therapies targeting autoimmune diseases.
Offering Details
The public offering included 11,500,000 shares of common stock, with 1,500,000 shares issued due to the underwriters' full exercise of their option. The table below summarizes the key financial metrics of the transaction:
| Metric | Value |
|---|---|
| Total shares offered | 11,500,000 |
| Price per share | $15.00 |
| Gross proceeds | $172.5 million |
| Underwriters' option shares | 1,500,000 |
Regulatory and Underwriting Information
The securities were offered pursuant to a shelf registration statement on Form S-3, which was declared effective by the Securities and Exchange Commission (SEC) on May 15, 2026. A final prospectus supplement and accompanying prospectus have been filed with the SEC and are available for review.
Jefferies, TD Cowen, and UBS Investment Bank acted as joint book-running managers for the offering. LifeSci Capital served as passive book-running manager, while BTIG acted as lead manager. The offering was conducted exclusively through the prospectus supplement and accompanying prospectus.
What are the specific timelines for the upcoming clinical trials that this capital will fund?
How might this capital injection influence Jade Biosciences' partnerships or collaborations with other biotech firms?
What are the potential market reactions to the full exercise of the underwriters' option?
17
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
